Synthesis and immunogenicity of hepatitis B virus envelope antigen expressed by recombinant vaccinia virus. Finding of retention signal in the C-terminal portion of the preS1 domain of subtype adyw
Jazyk angličtina Země Rakousko Médium print
Typ dokumentu časopisecké články
PubMed
1759909
DOI
10.1007/bf01316742
Knihovny.cz E-zdroje
- MeSH
- buněčné linie MeSH
- DNA virů MeSH
- hepatitida B - antigeny povrchové biosyntéza genetika imunologie MeSH
- imunizace MeSH
- klonování DNA MeSH
- krysa rodu Rattus MeSH
- molekulární sekvence - údaje MeSH
- myši MeSH
- peptidy genetika MeSH
- plazmidy MeSH
- precipitinové testy MeSH
- proteinové prekurzory genetika imunologie MeSH
- proteiny - lokalizační signály genetika imunologie MeSH
- protilátky virové imunologie MeSH
- regulace exprese virových genů MeSH
- sekvence nukleotidů MeSH
- Southernův blotting MeSH
- virus hepatitidy B genetika imunologie MeSH
- virus vakcinie genetika MeSH
- zvířata MeSH
- Check Tag
- krysa rodu Rattus MeSH
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- DNA virů MeSH
- hepatitida B - antigeny povrchové MeSH
- peptidy MeSH
- presurface protein 1, hepatitis B surface antigen MeSH Prohlížeč
- presurface protein 2, hepatitis B surface antigen MeSH Prohlížeč
- proteinové prekurzory MeSH
- proteiny - lokalizační signály MeSH
- protilátky virové MeSH
Five different recombinant vaccinia viruses expressing the envelope antigen of hepatitis B virus (HBsAg) under the control of the P7.5 promoter were constructed. Cell cultures infected with some of the recombinant viruses synthesized both middle (M) and major surface (S) protein of HBsAg. It was shown that the length of the nontranslated sequence preceding preS2-ATG influenced the extracellular or intracellular HBV antigen distribution and the preS2:S antigen ratio. Some recombinants synthesized an M protein that was enlarged by additional 35 amino acids of preS1 domain and was entirely retained within the infected cells. Antibody responses to the S and preS2 antigens in mice revealed significant differences in the immunogenicity of individual recombinants.
Zobrazit více v PubMed
J Virol. 1984 Nov;52(2):396-402 PubMed
Intervirology. 1987;28(1):14-25 PubMed
Nature. 1970 Aug 15;227(5259):680-5 PubMed
J Virol. 1987 Apr;61(4):1286-90 PubMed
Dokl Akad Nauk SSSR. 1986;289(6):1493-6 PubMed
Vaccine. 1989 Jun;7(3):234-6 PubMed
Acta Virol. 1969 May;13(3):209-15 PubMed
Nature. 1979 Dec 6;282(5739):575-9 PubMed
Adv Virus Res. 1988;34:65-142 PubMed
Proc Natl Acad Sci U S A. 1986 May;83(9):2850-4 PubMed
Arch Virol. 1990;112(3-4):181-93 PubMed
Annu Rev Immunol. 1987;5:305-24 PubMed
J Virol. 1986 Nov;60(2):337-44 PubMed
Mol Cell Biol. 1989 Oct;9(10):4459-66 PubMed
Arch Virol. 1990;113(3-4):283-9 PubMed
J Virol. 1982 Apr;42(1):100-5 PubMed
Science. 1986 Dec 12;234(4782):1388-91 PubMed
Proc Natl Acad Sci U S A. 1986 Dec;83(23):9174-8 PubMed
J Med Virol. 1986 Oct;20(2):111-25 PubMed
Nature. 1979 May 3;279(5708):43-7 PubMed
Vaccine. 1986 Mar;4(1):35-7 PubMed